Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa

References

• Cuenca N, Fernandez-Sanchez L, Campello L, et al. Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog Retin Eye Res 2014;43:17–75.
   PubMed Web of Science ®Google Scholar
• Smith J, Ward D, Michaelides M, et al. New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review. Eye (Lond) 2015;29:1131–40.
   PubMed Web of Science ®Google Scholar
• Natarajan S. Retinitis pigmentosa: a brief overview. Indian J Ophthalmol 2011;59:343–6.
   PubMed Web of Science ®Google Scholar
• Chizzolini M, Galan A, Milan E, et al. Good epidemiologic practice in retinitis pigmentosa: from phenotyping to biobanking. Curr Genomics 2011;12:260–6.
   PubMed Web of Science ®Google Scholar
• London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol 2013;9:44–53.
   PubMed Web of Science ®Google Scholar
• Hippert C, Graca AB, Barber AC, et al. Müller glia activation in response to inherited retinal degeneration is highly varied and disease-specific. PLoS One 2015;10:e0120415.
   PubMed Web of Science ®Google Scholar
• Jindal V. Interconnection between brain and retinal neurodegenerations. Mol Neurobiol 2015;51:885–92.
   PubMed Web of Science ®Google Scholar
• Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519–27.
   PubMedGoogle Scholar
• Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373–84.
   PubMed Web of Science ®Google Scholar
• Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007;32:577–95.
   PubMed Web of Science ®Google Scholar
• Perezleon JA, Osorio-Paz I, Francois L, Salceda R. Immunohistochemical localization of glycogen synthase and GSK3β: control of glycogen content in retina. Neurochem Res 2013;38:1063–9.
   PubMed Web of Science ®Google Scholar
• Li Z, Ma L, Chen X, et al. Glycogen synthase kinase-3: a key kinase in retinal neuron apoptosis in early diabetic retinopathy. Chin Med J (Engl Ed) 2014;127:3464–70.
   PubMed Web of Science ®Google Scholar
• Russo R, Adornetto A, Cavaliere F, et al. Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury. Mol Vis 2015;21:718–29.
   PubMed Web of Science ®Google Scholar
• Sun XB, Lu HE, Chen Y, et al. Effect of lithium chloride on endoplasmic reticulum stress-related PERK/ROCK signaling in a rat model of glaucoma. Pharmazie 2014;69:889–93.
   PubMed Web of Science ®Google Scholar
• De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002;43:1158–64.
   PubMed Web of Science ®Google Scholar
• Kumar A, Midha N, Gogia V, et al. Efficacy of oral valproic acid in patients with retinitis pigmentosa. J Ocul Pharmacol Ther 2014;30:580–6.
   PubMed Web of Science ®Google Scholar
• Iraha S, Hirami Y, Ota S, et al. Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study. Clin Ophthalmol 2016;10:1375–84.
   PubMed Web of Science ®Google Scholar
• Daly C, Yin J, Kennedy BN. Histone deacetylase: therapeutic targets in retinal degeneration. Adv Exp Med Biol 2016;854:455–61.
   PubMed Web of Science ®Google Scholar
• Martinez A, Perez DI, Gil C. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. Curr Top Med Chem 2013;13:1808–19.
   PubMed Web of Science ®Google Scholar
• Martínez A, Dorronsoro DI, Alonso CM, Panizo DPG, Fuertes HA, Perez PMJ, et al. Thiadiazolidinones as gsk-3 inhibitors, WO2005097117; 2005.
   Google Scholar
• Arroba AI, Wallace D, Mackey A, et al. IGF-I maintains calpastatin expression and attenuates apoptosis in several models of photoreceptor cell death. Eur J Neurosci 2009;30:975–86.
   PubMed Web of Science ®Google Scholar
• Corrochano S, Barhoum R, Boya P, et al. Attenuation of vision loss and delay in apoptosis of photoreceptors induced by proinsulin in a mouse model of retinitis pigmentosa. Investig Ophthalmol Vis Sci 2008;49:4188–94.
   PubMed Web of Science ®Google Scholar
• Kawasumi M, Nghiem P. Chemical genetics: elucidating biological systems with small-molecule compounds. J Investig Dermatol 2007;127:1577–84.
   PubMed Web of Science ®Google Scholar
• Palomo V, Perez DI, Perez C, et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem 2012;55:1645–61.
   PubMed Web of Science ®Google Scholar
• Perez DI, Palomo V, Perez C, et al. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. J Med Chem 2011;54:4042–56.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02586935?term=tideglusib&rank=2 [accessed July 2016].
   Google Scholar
• Redondo M, Palomo V, Brea J, et al. Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. ACS Chem Neurosci 2012;3:793–803.
   PubMed Web of Science ®Google Scholar
• Morales-Garcia JA, Luna-Medina R, Alonso-Gil S, et al. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci 2012;3:963–71.
   PubMed Web of Science ®Google Scholar
• Sereno L, Coma M, Rodriguez M, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009;35:359–67.
   PubMed Web of Science ®Google Scholar
• Bolos M, Fernandez S, Torres-Aleman I. Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels. J Biol Chem 2010;285:17693–700.
   PubMed Web of Science ®Google Scholar
• Barhoum R, Martinez-Navarrete G, Corrochano S, et al. Functional and structural modifications during retinal degeneration in the rd10 mouse. Neuroscience 2008;155:698–713.
   PubMed Web of Science ®Google Scholar
• Xin H, Yannazzo JA, Duncan RS, et al. A novel organotypic culture model of the postnatal mouse retina allows the study of glutamate-mediated excitotoxicity. J Neurosci Methods 2007;159:35–42.
   PubMed Web of Science ®Google Scholar
• Ha S, Ryu HY, Chung KM, et al. Regulation of autophagic cell death by glycogen synthase kinase-3β in adult hippocampal neural stem cells following insulin withdrawal. Mol Brain 2015;8:30.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014;29:479–87.
   PubMed Web of Science ®Google Scholar